Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Status:
Completed
Trial end date:
2015-09-15
Target enrollment:
Participant gender:
Summary
For subjects in Europe that have already participated in either Study SPD503-315 or
SPD503-316. This is an extension study that will allow participants access to
Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years. This study will help the
sponsor evaluate long-term safety and tolerability of Extended-release Guanfacine HCl
(SPD503).